MARKET

OPK

OPK

Opko Health
NASDAQ
1.180
+0.010
+0.85%
Closed 19:58 03/06 EST
OPEN
1.160
PREV CLOSE
1.170
HIGH
1.190
LOW
1.152
VOLUME
2.57M
TURNOVER
0
52 WEEK HIGH
2.035
52 WEEK LOW
1.110
MARKET CAP
895.70M
P/E (TTM)
-3.9268
1D
5D
1M
3M
1Y
5Y
1D
OPKO Health Price Target Cut to $1.50/Share From $2.25 by Barrington Research
Dow Jones · 6d ago
OPKO Health Is Maintained at Outperform by Barrington Research
Dow Jones · 6d ago
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5
Benzinga · 6d ago
Opko Health price target lowered to $1.50 from $2.25 at Barrington
TipRanks · 6d ago
H.C. Wainwright Reaffirms Their Buy Rating on Opko Health (OPK)
TipRanks · 6d ago
Weekly Report: what happened at OPK last week (0223-0227)?
Weekly Report · 6d ago
OPKO Health (OPK) Loss Worsens To US$0.30 TTM EPS Challenging Turnaround Narratives
Simply Wall St · 02/28 01:30
Opko Health Bets on Pipeline as Near-Term Profits Fade
TipRanks · 02/28 00:11
More
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.